查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830371

基因組編輯市場（按技術、應用、最終用戶、治療領域和交付方式）—2025-2032 年全球預測

Genome Editing Market by Technology, Application, End User, Therapeutic Area, Delivery Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年基因組編輯市場規模將達到 5,434.6 億美元，複合年成長率為 54.73%。

主要市場統計數據
基準年2024年 165.4億美元
預計2025年 257.8億美元
預測年份：2032年 5434.6億美元
複合年成長率（%） 54.73%

對基因組編輯生態系統轉型的簡明而權威的定位，將科學進步與營運和政策現實結合

基因組編輯已從實驗室的一項小眾技術發展成為現代生命科學的核心支柱，改變了研究範式、治療方法的開發和農業創新。過去十年，精準編輯化學和遞送系統的進步，提高了攻克先前難以攻克的基因標靶的可行性。因此，轉化研究管道已擴展至基因校正、細胞工程以及作物和牲畜的性狀改良，而工業生產也開始利用基因編輯生物體進行更高價值的生物製造。

因此，如今的生態系統涵蓋了學術實驗室、合約研究組織、生物技術公司和大型製藥公司。每個相關人員需要差異化的證據：研究人員需要實驗室級檢驗，產業需要可擴展的生產方法，商業開發需要監管和報銷資訊。因此，整合技術能力、特定應用的限制和監管環境對於做出明智的決策至關重要。

此外，地緣政治和貿易動態為供應鏈和資本配置帶來了新的變數。這些外部壓力與技術進步相互作用，影響基因組編輯創新的開發、測試和商業化的地點和方式。因此，讀者應該期待一份全面的評估，將科學發展軌跡與政策變化以及與市場相關的營運考量聯繫起來。

深入綜合科學、監管和營運方面的變化，重新定義基因組編輯領域的優先事項和價值創造

基因組編輯領域正在經歷多重變革，這些變革正在重塑研究重點和商業策略。首先，編輯平台精度和安全性的提升正在改變治療和農業應用的風險效益計算，推動研究從發現研究轉向轉化研究和臨床研究。這種轉變凸顯了遞送技術和有效載荷最佳化作為提升臨床可行性的關鍵因素的重要性。

其次，編輯系統的模組化和互通性正在加速創新週期。鹼基編輯器、Prime 編輯器和 CRISPR 特異性核酸酶等平台可以與不斷發展的遞送載體結合，創造出針對不同目標的解決方案，從而使更廣泛的相關人員能夠追求差異化的價值提案。因此，我們看到分子生物學家、遞送專家和製程工程師之間的跨學科合作日益增多。

第三，法律規範正在不斷調整，世界各地的機構正在改善其關於安全性評估、脫靶評估和長期追蹤要求的指導。這些監管細化正在影響研發時間表和所需證據，同時也為研發機構和監管機構之間更早的對話鋪平了道路。同時，社會和投資者日益嚴格的審查也使得透明的安全數據和強大的患者參與策略變得尤為重要。

最後，宏觀經濟和貿易因素促使企業重新評估其供應鏈、試劑採購和生產佈局。為此，企業正在多元化供應商關係，並投資於區域能力建設，以減少外部衝擊的影響。總而言之，這些轉變需要企業制定靈活的策略，將科學的願景與務實的產業計畫結合。

對 2025 年關稅如何改變整個基因組編輯價值鏈的供應鏈、籌資策略和營運決策的批判性分析

關稅制度和跨境貿易的政策變化對基因組編輯生態系統有重大影響，會影響試劑流通、設備進口和下游製造成本基礎。 2025年徵收的累積關稅強化了供應鏈韌性和供應商多元化的重要性，因為企業在酶、核酸合成服務和專用實驗室設備等關鍵投入方面面臨更長的前置作業時間和更高的累積成本。

因此，各公司加快了在地化進程，並尋求具備區域能力的替代供應商。同時，採購團隊採取了多方採購策略和長期契約，以穩定供應和價格風險。這些調整影響了計劃排序和資本配置決策，尤其對於那些臨床研發管線時間緊迫的公司。

此外，關稅主導的成本壓力改變了儀器和試劑製造商與其下游客戶之間的談判動態。為了保持競爭力，一些供應商透過提供配套服務、靈活資金籌措或在岸組裝選項來應對。從策略角度來看，這些發展增強了垂直整合模式和內部製造能力對尋求控制關鍵製造流程的大型機構的吸引力。

此外，關稅的影響因應用程式和最終用戶而異，學術機構和小型開發商通常比資金雄厚的製藥公司更容易受到直接成本上漲的影響。因此，聯合採購共用和共享核心設施已成為切實可行的應對措施，使多個組織能夠分攤固定成本，並在關稅相關干擾的情況下保持對關鍵技術的獲取。

策略性細分框架，細分技術、應用、最終用戶、治療領域和交付方法，以確定可行的計劃和投資影響

細分市場提供了將科學細微差別轉化為商業性洞察所需的分析框架。按技術細分，市場包括鹼基編輯，包括腺嘌呤和胞嘧啶鹼基編輯亞型；CRISPR系統進一步細分為Cas12、Cas13和Cas9變體；prime編輯；Megatal、TALEN和ZFN，每種技術在精度、有效載荷限制和脫靶率方面都呈現出不同的技術權衡。這種細分至關重要，因為平台屬性決定了下游在遞送、標靶選擇和安全測試方面的選擇，從而影響可行的適應症類型和方案設計。

按應用分類，主要發展軌跡涵蓋以作物和牲畜改良為重點的農業應用、生質燃料和生物製造等工業生物技術用例、涵蓋基礎研究和藥物發現的研究應用，以及包括細胞和基因治療在內的治療應用。這些應用領域需要不同的依證，農業和工業優先考慮性狀穩定性和規模化，而治療開發者則強調臨床安全性、有效性和監管合規性。

就最終用戶而言，生態系統涵蓋學術研究機構、合約研究組織和製藥/生物技術公司，每個公司都有不同的營運模式、資金週期和擴大規模的能力：學術中心通常充當創新中心和早期概念驗證的生成器，CRO 提供專業知識和可擴展的執行，而製藥/生物技術公司則專注於商業開發和監管途徑。

治療領域細分可識別出生物複雜性、患者群體和臨床試驗設計考量差異顯著的優先領域，例如循環系統、遺傳疾病、感染疾病、神經病學和腫瘤學。遞送方法細分則進一步明確了可行性。電穿孔和脂質奈米顆粒等非病毒方法可提供瞬時表現圖譜並降低免疫抗原性風險，基因槍和顯微注射等物理方法可實現體外操作和局部遞送，而病毒載體策略對於持續體內表達至關重要。了解這些細分視角如何交織，有助於相關人員根據目標適應症和開發策略調整平台選擇。

區域比較分析揭示了不同的法規環境、製造能力和研究生態系統如何影響全球市場的基因組編輯策略

區域動態對技術應用、監管策略和夥伴關係模式具有決定性的影響。在美洲，強勁的創業投資活動、集中的臨床試驗基礎設施以及密集的轉化研究中心網路，支持著新型編輯療法從發現到早期臨床開發的快速發展。這些區域優勢使美洲成為加速轉化勢頭的合作科學網路和大型生物技術叢集的中心。

跨多個司法管轄區的監管協調以及多元化的支付方格局正在塑造歐洲、中東和非洲地區（EMEA）的研發策略。歐洲研究機構持續為基礎科學進步做出貢獻，而新興企業和大型製藥公司則需應對複雜的報銷和倫理框架。同時，對生產能力的投資和策略性官民合作關係正成為維持先進療法競爭力的途徑。

亞太地區正在拓展其研究和商業化途徑，其生產能力迅速提升，技術精湛的科學家數量不斷增加，政府也積極支持生物技術創新。此外，由於地區間監管時限和臨床試驗入組動態的差異，跨國研發公司正在採取靈活的臨床策略，利用該地區的優勢，加快患者招募速度，並實現經濟高效的研發。

在全部區域，相關人員擴大採用混合策略，將本地能力與跨境夥伴關係相結合，以最佳化人才、資本和患者群體的獲取，同時管理區域監管和供應鏈差異。

我們清楚檢驗推動平台創新者、治療開發商、服務供應商、製造專家等競爭定位的策略。

基因組編輯領域的公司層面動態反映了一系列原型，從平台技術先驅到垂直整合開發商，再到專業服務供應商。以平台為中心的公司專注於提高編輯特異性、擴大標靶覆蓋範圍，並建立可授權或合作用於各種應用的模組化系統。這些公司通常在研發方面投入巨資，並在鹼基編輯、主要編輯和核酸酶最佳化等核心技術領域中保持主導地位。

治療開發公司通常採用許可和合作的方式，將其平台優勢與臨床和監管專業知識相結合，以加速將早期發現轉化為臨床候選藥物。服務供應商和合約委外研發機構正在透過捆綁端到端功能（包括標靶驗證、交付最佳化和符合GLP的安全性測試）來適應這一趨勢，為希望外包技術複雜性的贊助商提供承包解決方案。

製造和供應鏈專業人員也在不斷發展，透過投資可擴展的填充、載體生產和品質系統來支持先進療法的生產。此外，他們也越來越重視策略夥伴關係，將平台所有者與製造專家和商業合作夥伴聯繫起來，以降低後期開發風險並擴大市場准入。總而言之，這些企業級策略展現了生態系統參與者如何定位自身，以便在從創新到商業化的不同階段中獲得價值。

為高階主管提供以行動為導向的策略指導，幫助他們協調技術開發、夥伴關係、監管參與和營運彈性，實現永續成長

產業領導者必須採取多管齊下的務實策略，將技術前景轉化為商業性成功。首先，對遞送創新和有效載荷工程的投資至關重要，因為改進編輯系統到達目標細胞和組織的方式將對臨床可行性和農業應用成果產生重大影響。公司應在專案設計早期優先整合編輯化學和遞送方法，以降低下游開發風險。

其次，領導者應尋求靈活的合作模式，在獨立控制與合作研究的實際效益之間取得平衡。與專業的委外研發機構、生產合作夥伴和區域開發中心建立策略聯盟，可以加快臨床試驗的進度，同時保留商業化選擇。同時，培養強大的監管能力，並在開發早期與監管機構合作，可以鋪平核准之路，並明確可接受的安全終點。

第三，上市公司必須透過供應鏈多元化、區域生產計畫和長期供應商協議來增強營運韌性。這些措施將減輕貿易中斷帶來的風險，並確保臨床和商業項目的連續性。此外，上市公司應加強其資料管治和道德監督框架，以維護公眾信任並滿足不斷變化的社會期望。

最後，公司應基於清晰的市場進入策略來制定投資決策，該策略應考慮治療領域的複雜性、患者招募動態和報銷方案。將平台優勢與兼具科學合理性、監管可行性和商業性潛力的適應症相匹配，使領導者能夠優先考慮未來影響最大、資源效率最高的項目。

透明而嚴謹的混合方法研究途徑結合了專家訪談、技術文獻綜合和基於場景的分析，檢驗了研究結果

調查方法結合了定性方法以及來自一手和二手研究的嚴格證據整合，旨在為基因組編輯生態系統提供堅實的洞見。一手研究包括與來自學術機構、受託研究機構、生物技術開發公司和療法申辦方的主題專家進行結構化訪談。這些訪談提供了關於實際限制、發展時間表和策略重點的背景資訊，而這些資訊在一般文獻中並不常見。

我們的二手資料研究綜合了同行評審的出版物、監管指南文件、專利申請和企業資料披露資訊，構建了全面的技術和政策敘述。在適當的情況下，我們查閱了技術白皮書、會議論文集和預印本文獻，以了解編輯平台和交付系統的最新進展。對這些資訊來源的三角檢驗確保了我們的結論是基於可重複的證據和同行檢驗。

本研究採用的分析架構包括技術就緒評估、價值鏈映射和基於情境的風險分析。透過迭代同儕審查進行敏感度檢查，並透過跨部門研討會檢驗研究結果，以確保研究結果與研發和商業相關人員相關者的相關性。主要訪談內容均採取保密措施，以保護個人獨特意見並鼓勵坦誠評論。

將技術創新與監管、道德和營運要求相結合的簡明綜合體，以指導決策者制定有影響力的計劃

基因組編輯的發展軌跡體現了許多因素的匯聚：編輯化學技術的精進、交付方式的成熟、監管預期的演變以及經濟壓力的變化。這些因素共同創造了一個充滿活力的環境，其中策略敏捷性、技術力和營運穩健性將決定哪些專案能夠成功地從概念轉化為實際影響。要駕馭這種環境，相關人員需要在平台重點、夥伴關係結構和地理部署方面做出審慎的選擇。

重要的是，無論是在治療、農業或工業生物技術領域，短期內最有前景的機會是那些將技術可行性與清晰的轉化途徑結合的機會。同時，管理供應鏈風險以及投資合規和道德管治對於維持長期發展動能至關重要。綜合考慮技術、監管和商業性因素，組織能夠優先考慮最有可能帶來有意義的科學和社會效益的努力。

最終，基因組編輯的成功不僅取決於科學突破，還取決於組織負責任、有彈性地大規模實施這些突破的能力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 鹼基編輯和主要編輯技術的進步，可實現精確的單鹼基修改
  • 整合人工智慧驅動的生物資訊平台來指導 CRISPR 標靶選擇
  • 用於體內治療的非病毒遞送系統的開發
  • 協調監管努力，推動基因編輯療法獲得全球核准
  • 圍繞生殖系應用的倫理和社會問題
  • 擴大 CRISPR 診斷技術，用於快速檢測和監測感染疾病
  • 將基因編輯細胞療法商業化用於治療血液疾病和癌症
  • 開展昆蟲基因驅動計劃，用於媒介傳播疾病控制和生態學風險評估
  • 抗CRISPR蛋白作為基因組編輯通訊協定中的安全開關的出現
  • 多重基因組編輯技術在細胞內建構複雜基因迴路的進展
  • 生物製藥公司與科技公司之間的策略合作加速研究
  • 最高法院最近就 CRISPR 智慧財產權做出裁決後，專利格局正在改變

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 基因組編輯市場（按技術）

  • 鹼基編輯
    • 腺嘌呤鹼基編輯
    • 胞嘧啶鹼基編輯
  • CRISPR
    • Cas12
    • Cas13
    • Cas9
  • 巨型行星
  • Prime Edit
  • 塔倫
  • Zfn

第9章 基因組編輯市場（按應用）

  • 農業
    • 作物改良
    • 牲畜改良
  • 工業生物技術
    • 生質燃料
    • 生物製造
  • 研究
    • 基礎研究
    • 藥物研發
  • 治療藥物
    • 細胞療法
    • 基因治療

第 10 章 基因組編輯市場（依最終使用者分類）

  • 學術機構
  • 合約研究組織
  • 製藥生物技術

第 11 章 基因組編輯市場（依治療領域）

  • 心臟病學
  • 遺傳性疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第 12 章。按交付方式分類的基因組編輯市場

  • 非病毒
    • 電穿孔
    • 脂質奈米顆粒
  • 物理方法
    • 基因槍
    • 顯微注射
  • 病毒載體

第13章 基因組編輯市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 基因組編輯市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章 各國基因組編輯市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Lonza Group AG
    • Sartorius AG
    • Becton Dickinson and Company
    • CRISPR Therapeutics AG
    • Intellia Therapeutics, Inc.
    • Sangamo Therapeutics, Inc.
Product Code: MRR-431C35F6C15D

The Genome Editing Market is projected to grow by USD 543.46 billion at a CAGR of 54.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.54 billion
Estimated Year [2025] USD 25.78 billion
Forecast Year [2032] USD 543.46 billion
CAGR (%) 54.73%

A concise and authoritative orientation to the transforming genome editing ecosystem that integrates scientific advances with operational and policy realities

Genome editing has evolved from a niche laboratory capability into a central pillar of modern life sciences, transforming research paradigms, therapeutic development, and agricultural innovation. Over the past decade, advances in precision editing chemistries and delivery systems have increased the feasibility of addressing previously intractable genetic targets. As a result, translational pipelines have broadened to include gene correction, cell engineering, and trait improvement in crops and livestock, while industrial processes have begun to leverage edited organisms for higher-value biomanufacturing.

Consequently, the ecosystem now spans academic laboratories, contract research organizations, biotechnology firms, and large pharmaceutical companies. Each stakeholder group demands differentiated evidence: bench-level validation for researchers, scalable manufacturing approaches for industry, and regulatory and reimbursement intelligence for commercial development. Thus, an integrated synthesis of technological capabilities, application-specific constraints, and regulatory context is essential for informed decision-making.

Moreover, geopolitical and trade dynamics have introduced new variables into supply chains and capital allocation. These external pressures interact with technical progress to influence where and how genome editing innovations are developed, tested, and commercialized. Therefore, readers should expect a holistic assessment that connects scientific trajectories with policy shifts and market-relevant operational considerations.

An in-depth synthesis of scientific, regulatory, and operational shifts that are redefining priorities and value creation across the genome editing landscape

The landscape of genome editing is undergoing multiple transformative shifts that are reshaping research priorities and commercial strategies. First, precision and safety improvements in editing platforms have altered risk-benefit calculations across therapeutic and agricultural applications, prompting a move from exploratory research toward translational and clinical programs. This transition has elevated the importance of delivery technologies and payload optimization as critical enablers of clinical viability.

Second, modularity and interoperability of editing systems are accelerating innovation cycles. Platforms such as base editors, prime editors, and CRISPR-focused nucleases can be combined with evolving delivery vehicles to create tailored solutions for diverse targets, thereby enabling a wider set of stakeholders to pursue differentiated value propositions. Consequently, cross-disciplinary collaboration between molecular biologists, delivery specialists, and process engineers is increasing.

Third, regulatory frameworks are adapting, with agencies worldwide refining guidance on safety assessments, off-target evaluation, and long-term follow-up requirements. These regulatory refinements are influencing development timelines and evidentiary needs, while also opening pathways for earlier dialog between developers and regulators. Simultaneously, heightened public and investor scrutiny places a premium on transparent safety data and robust patient engagement strategies.

Finally, macroeconomic and trade factors are prompting organizations to reassess supply chains, reagent sourcing, and manufacturing footprints. In response, firms are diversifying vendor relationships and investing in regional capabilities to mitigate exposure to external shocks. Taken together, these shifts demand agile strategies that integrate scientific foresight with pragmatic operational planning.

A rigorous analysis of how 2025 tariff measures have reshaped supply chains, procurement strategies, and operational decision-making across the genome editing value chain

Policy shifts in tariff regimes and cross-border trade have material implications for the genome editing ecosystem, affecting reagent flows, instrument imports, and the cost base of downstream manufacturing. Cumulative tariffs imposed in 2025 have amplified the importance of supply chain resilience and vendor diversification, as companies experienced increased lead times and higher landed costs for critical inputs such as enzymes, nucleic acid synthesis services, and specialized laboratory equipment.

As a result, organizations have accelerated localization efforts and sought alternative suppliers with regional capacity. In parallel, procurement teams have adopted multi-sourcing strategies and longer-term contracting to stabilize supply and price exposure. These adjustments have influenced project sequencing and capital allocation decisions, particularly for firms managing clinical pipelines with tight timelines.

Moreover, tariff-driven cost pressures have shifted negotiation dynamics between manufacturers of instruments and reagents and their downstream customers. Some suppliers responded by offering bundled services, flexible financing, or on-shore assembly options to maintain competitiveness. From a strategic perspective, these developments have increased the appeal of vertically integrated models and in-house manufacturing capabilities for larger institutions seeking to control critical production steps.

In addition, tariff impacts have varied across applications and end users, with academic institutes and smaller developers often more exposed to immediate cost increases than well-capitalized pharmaceutical partners. Consequently, collaborative procurement consortia and shared core facilities have emerged as pragmatic responses, allowing multiple organizations to spread fixed costs and maintain access to key technologies despite tariff-related disruptions.

A strategic segmentation framework that dissects technology, application, end-user, therapeutic area, and delivery method to reveal actionable program and investment implications

Segmentation provides the analytical scaffolding needed to translate scientific nuance into commercial insight. When analyzed by technology, the market includes Base Editing with its Adenine Base Editor and Cytosine Base Editor subtypes, CRISPR systems further differentiated into Cas12, Cas13, and Cas9 variants, Prime Editing, Megatal, TALEN, and ZFN, each presenting distinct technical trade-offs in precision, payload constraints, and off-target profiles. This granularity is critical because platform attributes determine downstream choices in delivery, target selection, and safety testing, thereby influencing the types of indications and program designs that are feasible.

When framed by application, key trajectories emerge across Agricultural applications focused on Crop Improvement and Livestock Improvement, Industrial Biotechnology use cases such as Biofuels and Biomanufacturing, Research applications that span Basic Research and Drug Discovery, and Therapeutics encompassing Cell Therapy and Gene Therapy. These application segments require different evidence bases, with agricultural and industrial players prioritizing trait stability and scale, while therapeutic developers emphasize clinical safety, efficacy, and regulatory alignment.

In terms of end users, the ecosystem spans Academic Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology companies, each with distinct operational models, funding cycles, and access to scale-up capabilities. Academic centers often act as innovation hubs and early proof-of-concept generators, CROs provide specialized expertise and scalable execution, and pharmaceutical and biotech firms focus on commercial development and regulatory pathways.

Therapeutic area segmentation identifies priority domains including Cardiology, Genetic Disorders, Infectious Diseases, Neurology, and Oncology, which differ markedly in biological complexity, patient populations, and clinical trial design considerations. Delivery method segmentation further clarifies feasibility: Nonviral approaches such as Electroporation and Lipid Nanoparticles offer transient expression profiles and reduced immunogenicity risks, Physical Methods like Gene Gun and Microinjection enable ex vivo manipulation or localized delivery, and Viral Vector strategies remain essential for durable in vivo expression. Understanding how these segmentation lenses intersect enables stakeholders to align platform selection with target indications and development strategies.

A comparative regional analysis highlighting how distinct regulatory environments, manufacturing capabilities, and research ecosystems shape genome editing strategies across global markets

Regional dynamics exert a decisive influence on technology adoption, regulatory strategy, and partnership models. In the Americas, strong venture capital activity, a concentration of clinical trial infrastructure, and a dense network of translational research centers have supported rapid progression of novel editing therapies from discovery into early clinical development. These regional strengths make the Americas a focal point for collaborative scientific networks and sizable biotech clusters that accelerate translational momentum.

In Europe, the Middle East & Africa region, regulatory harmonization across multiple jurisdictions and a diverse payer landscape shape development tactics. European research institutions continue to contribute foundational scientific advances while startups and larger pharmaceutical firms navigate complex reimbursement and ethical frameworks. Meanwhile, investments in manufacturing capacity and strategic public-private partnerships are emerging as levers to maintain competitiveness in advanced therapies.

In the Asia-Pacific, rapid scaling of manufacturing capability, a growing base of skilled scientists, and proactive government initiatives to support biotechnology innovation have led to expanding research and commercialization pathways. Additionally, regional differences in regulatory timelines and clinical trial enrollment dynamics have encouraged multinational developers to adopt flexible clinical strategies that leverage Asia-Pacific strengths for expedited patient recruitment and cost-efficient development.

Across these regions, stakeholders increasingly adopt hybrid strategies that combine local capabilities with cross-border partnerships, thereby optimizing access to talent, capital, and patient populations while managing regional regulatory and supply chain variability.

A clear-eyed examination of company strategies across platform innovators, therapeutic developers, service providers, and manufacturing specialists that drive competitive positioning

Company-level dynamics in genome editing reflect a spectrum of archetypes ranging from platform technology pioneers to vertically integrated developers and specialized service providers. Platform-focused firms concentrate on improving editing specificity, expanding target scope, and creating modular systems that can be licensed or partnered into diverse application areas. These organizations typically invest heavily in R&D to maintain lead positions in core technologies such as base editing, prime editing, and nuclease optimization.

Therapeutic developers often follow licensing and collaboration pathways to combine platform strengths with clinical and regulatory expertise, thereby accelerating the translation of early-stage discoveries into clinical candidates. Service providers and contract research organizations have adapted by bundling end-to-end capabilities that include target validation, delivery optimization, and GLP-compliant safety testing, creating turnkey solutions for sponsors seeking to outsource technical complexity.

Manufacturing and supply chain specialists are also evolving to support advanced therapy production, with investments in scalable fill-finish, vector production, and quality systems. In addition, there is a growing emphasis on strategic partnerships that align platform owners with manufacturing specialists and commercial partners to de-risk late-stage development and enable broader market access. Collectively, these company-level strategies illustrate how ecosystem participants position themselves to capture value at different points in the innovation-to-commercialization continuum.

Action-oriented strategic guidance for executives to align technology development, partnerships, regulatory engagement, and operational resilience for sustainable growth

Industry leaders must adopt multifaceted, pragmatic strategies to convert technological promise into commercial success. First, investing in delivery innovation and payload engineering is essential, because improvements in how editing systems reach target cells and tissues materially affect clinical feasibility and agricultural application outcomes. Companies should prioritize integration between editing chemistry and delivery modality early in program design to reduce downstream development risk.

Second, leaders should pursue flexible partnership models that balance proprietary control with the practical benefits of collaboration. Strategic alliances with specialized contract research organizations, manufacturing partners, and regional development hubs can accelerate time to clinic while preserving optionality for commercialization. In parallel, developing a robust regulatory affairs capability and engaging regulators early in development can smooth approval pathways and define acceptable safety endpoints.

Third, operational resilience must be elevated through supply chain diversification, regional manufacturing planning, and long-term supplier agreements. These measures mitigate exposure to trade disruptions and ensure continuity of clinical and commercial programs. Moreover, companies should strengthen data governance and ethical oversight frameworks to sustain public trust and meet evolving societal expectations.

Finally, firms should align investment decisions with clear go-to-market strategies that consider therapeutic area complexity, patient recruitment dynamics, and reimbursement scenarios. By matching platform strengths to indications where scientific rationale, regulatory feasibility, and commercial upside converge, leaders can prioritize programs with the highest prospective impact and resource efficiency.

A transparent and rigorous mixed-methods research approach that integrates expert interviews, technical literature synthesis, and scenario-based analysis to validate findings

The research methodology combines primary and secondary qualitative techniques with rigorous evidence synthesis to deliver robust insights into the genome editing ecosystem. Primary research includes structured interviews with domain experts across academic institutions, contract research organizations, biotechnology developers, and therapeutic sponsors. These dialogues provide context on practical constraints, development timelines, and strategic priorities that are not always evident in public literature.

Secondary research synthesizes peer-reviewed publications, regulatory guidance documents, patent filings, and corporate disclosures to construct a comprehensive technical and policy narrative. Where appropriate, technical white papers, conference proceedings, and preprint literature were reviewed to capture the most recent advances in editing platforms and delivery systems. Triangulation across these sources ensures that conclusions are grounded in reproducible evidence and expert validation.

Analytical frameworks employed in the study include technology readiness assessments, value-chain mapping, and scenario-based risk analysis. Sensitivity checks were performed through iterative expert review, and findings were validated through cross-sector workshops to ensure relevance to both R&D and commercial stakeholders. Confidentiality protocols were applied to primary interviews to protect proprietary inputs and encourage candid commentary.

A concise synthesis that connects technical innovation with regulatory, ethical, and operational imperatives to guide decision-makers toward impactful programs

The trajectory of genome editing is characterized by converging forces: technical refinement of editing chemistries, maturation of delivery approaches, evolving regulatory expectations, and shifting economic pressures. Together, these forces create a dynamic environment in which strategic agility, technical excellence, and operational robustness determine which programs progress successfully from concept to impact. As stakeholders navigate this environment, they will need to make disciplined choices about platform focus, partnership structures, and geographic deployment.

Importantly, the most promising near-term opportunities are those that effectively pair technical feasibility with clear translational pathways, whether in therapeutics, agriculture, or industrial biotechnology. Concurrently, managing supply chain exposure and investing in compliance and ethical governance will be critical to sustaining long-term momentum. By synthesizing technological, regulatory, and commercial considerations, organizations can prioritize initiatives with the highest potential to deliver meaningful scientific and societal benefits.

Ultimately, success in genome editing will be defined not only by scientific breakthroughs but by the capacity of organizations to operationalize those breakthroughs at scale, responsibly and resiliently.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in base and prime editing technologies for precise single-nucleotide modifications
  • 5.2. Integration of AI-driven bioinformatics platforms in guiding CRISPR target selection
  • 5.3. Development of nonviral delivery systems for in vivo genome editing therapies
  • 5.4. Regulatory harmonization efforts for global approval of gene editing therapeutics
  • 5.5. Ethical and societal challenges surrounding germline genome editing applications
  • 5.6. Expansion of CRISPR diagnostics in rapid infectious disease detection and surveillance
  • 5.7. Commercialization of gene edited cell therapies for hematological disorders and cancers
  • 5.8. Growth of insect gene drive projects for vector-borne disease control and ecological risk assessment
  • 5.9. Emergence of anti-CRISPR proteins as safety switches in genome editing protocols
  • 5.10. Advances in multiplex genome editing for engineering complex genetic circuits in cells
  • 5.11. Strategic partnerships between biopharma and tech companies to accelerate genome editing research
  • 5.12. Patent landscape shifts after recent Supreme Court rulings on CRISPR intellectual property

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genome Editing Market, by Technology

  • 8.1. Base Editing
    • 8.1.1. Adenine Base Editor
    • 8.1.2. Cytosine Base Editor
  • 8.2. Crispr
    • 8.2.1. Cas12
    • 8.2.2. Cas13
    • 8.2.3. Cas9
  • 8.3. Megatal
  • 8.4. Prime Editing
  • 8.5. Talen
  • 8.6. Zfn

9. Genome Editing Market, by Application

  • 9.1. Agricultural
    • 9.1.1. Crop Improvement
    • 9.1.2. Livestock Improvement
  • 9.2. Industrial Biotechnology
    • 9.2.1. Biofuels
    • 9.2.2. Biomanufacturing
  • 9.3. Research
    • 9.3.1. Basic Research
    • 9.3.2. Drug Discovery
  • 9.4. Therapeutics
    • 9.4.1. Cell Therapy
    • 9.4.2. Gene Therapy

10. Genome Editing Market, by End User

  • 10.1. Academic Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech

11. Genome Editing Market, by Therapeutic Area

  • 11.1. Cardiology
  • 11.2. Genetic Disorders
  • 11.3. Infectious Diseases
  • 11.4. Neurology
  • 11.5. Oncology

12. Genome Editing Market, by Delivery Method

  • 12.1. Nonviral
    • 12.1.1. Electroporation
    • 12.1.2. Lipid Nanoparticles
  • 12.2. Physical Methods
    • 12.2.1. Gene Gun
    • 12.2.2. Microinjection
  • 12.3. Viral Vector

13. Genome Editing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Genome Editing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Genome Editing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Agilent Technologies, Inc.
    • 16.3.5. Lonza Group AG
    • 16.3.6. Sartorius AG
    • 16.3.7. Becton Dickinson and Company
    • 16.3.8. CRISPR Therapeutics AG
    • 16.3.9. Intellia Therapeutics, Inc.
    • 16.3.10. Sangamo Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GENOME EDITING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GENOME EDITING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENOME EDITING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENOME EDITING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENOME EDITING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 338. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 340. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL ME